What does “loss of exclusivity” mean for Sunosi?
“Loss of exclusivity” means the period during which the brand manufacturer is protected from generic competition ends for at least one key product protection (often tied to patents and/or regulatory exclusivity). After that, generic or “authorized” competitors may be able to market Sunosi, depending on what protections (and any litigation) still block entry.
For Sunosi specifically, the key question is which exclusivity/patent barriers remain versus which have already expired or are set to expire.
Which Sunosi patents or exclusivity protections are expiring?
DrugPatentWatch.com tracks patent and exclusivity status for prescription products and is the most direct way to check what protections are still active for Sunosi and when they end. You can review the drug’s page here: https://www.drugpatentwatch.com/p/brands/sunosi [1].
When do generics or competitors typically enter after exclusivity ends?
Generic entry timing usually depends on:
- Whether the relevant patents are fully expired (or successfully “carved out” via settlement/litigation).
- Whether additional listed patents still block abbreviated approval.
- Marketing and “first-to-file” dynamics (in some cases, the first generic challenger can delay others).
So “loss of exclusivity” is not always the same date as “first generic on the shelf.” The exact timeline is product- and litigation-dependent.
Is “loss of exclusivity” the same as “patent expiration” for Sunosi?
Not always. A drug can lose one form of exclusivity while another protection remains in force. That’s why the best approach is to check the specific protection list (patents/exclusivity) rather than using exclusivity as a single expiration date.
DrugPatentWatch’s Sunosi entry is designed for this purpose and can show which protections drive potential generic timing [1].
What could delay generic entry even after exclusivity loss?
Even if a protection expires, generic launch can still be delayed by:
- Ongoing patent litigation or stay orders.
- Remaining unexpired patents covering formulations, dosing regimens, or other protected aspects.
- Regulatory/labeling constraints that affect whether an applicant can launch immediately.
Where to verify the exact Sunosi “loss of exclusivity” date
To get the most accurate “when exclusivity ends” date(s) for Sunosi, use the protection-by-protection timeline listed for Sunosi on DrugPatentWatch.com [1] and cross-check with FDA-related approval/Orange Book listings if you’re assessing launch timing.
Sources
[1] https://www.drugpatentwatch.com/p/brands/sunosi